Quantum technologies promise secure communication networks, powerful forms of computing and new sensing tools. One of the major challenges, however, is that different quantum systems often operate at ...

A new control protocol boosts fidelity in systems using Rydberg qubits, dynamically suppressing excitation while leveraging ...

ENIGMA-TRS 1 is a Phase 3 international, one-year, randomized, double-blind, placebo-controlled study in 600+ patients; 12-week study results ...

Excitons, correlated electron-hole pairs governing optical and transport properties in organic semiconductors, have long resisted direct experimental access to their full quantum-mechanical wave ...

Pyrotech Therapeutics ("Pyrotech" or the "Company"), a clinical-stage biopharmaceutical company pioneering innate immune modulation and pyroptosis-targeted therapies, announced that the first healthy ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of ...

A TWO-PHASE randomised clinical trial has shown that low-dose hydrocortisone acutely sharpens verbal learning, memory and ...

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last ...

Independent, government-funded research in Scientific Reports shows oral YK-4-250 improves survival and intestinal ...

PrimeBOT brings the world’s smallest humanoid and transforming quadrupedal robot to IFA 2026 and wins the Innovation Award at ...

Newron completes screening for enrollment in pivotal phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia: Milan, Italy T ...